JP2011500024A - Ｒｐｅ細胞を生成する改良された方法およびｒｐｅ細胞の組成物 - Google Patents

Ｒｐｅ細胞を生成する改良された方法およびｒｐｅ細胞の組成物 Download PDF

Info

Publication number
JP2011500024A
JP2011500024A JP2010528899A JP2010528899A JP2011500024A JP 2011500024 A JP2011500024 A JP 2011500024A JP 2010528899 A JP2010528899 A JP 2010528899A JP 2010528899 A JP2010528899 A JP 2010528899A JP 2011500024 A JP2011500024 A JP 2011500024A
Authority
JP
Japan
Prior art keywords
cells
rpe cells
rpe
formulation
medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010528899A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500024A5 (enExample
Inventor
クリストファー マルクイト，
リンダ レミウクス，
ウィリアム ホルメス，
ペドロ ウェルタス，
ルーシー ビルナー，
Original Assignee
アドバンスド セル テクノロジー， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アドバンスド セル テクノロジー， インコーポレイテッド filed Critical アドバンスド セル テクノロジー， インコーポレイテッド
Publication of JP2011500024A publication Critical patent/JP2011500024A/ja
Publication of JP2011500024A5 publication Critical patent/JP2011500024A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/73—Hydrolases (EC 3.)
    • C12N2501/734—Proteases (EC 3.4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010528899A 2007-10-12 2008-10-10 Ｒｐｅ細胞を生成する改良された方法およびｒｐｅ細胞の組成物 Withdrawn JP2011500024A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US99866807P 2007-10-12 2007-10-12
US99876607P 2007-10-12 2007-10-12
US991108P 2008-01-02 2008-01-02
US990808P 2008-01-02 2008-01-02
PCT/US2008/011669 WO2009051671A1 (en) 2007-10-12 2008-10-10 Improved methods of producing rpe cells and compositions of rpe cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014125977A Division JP6137626B2 (ja) 2007-10-12 2014-06-19 Ｒｐｅ細胞を生成する改良された方法およびｒｐｅ細胞の組成物

Publications (2)

Publication Number Publication Date
JP2011500024A true JP2011500024A (ja) 2011-01-06
JP2011500024A5 JP2011500024A5 (enExample) 2012-11-15

Family

ID=40567677

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2010528899A Withdrawn JP2011500024A (ja) 2007-10-12 2008-10-10 Ｒｐｅ細胞を生成する改良された方法およびｒｐｅ細胞の組成物
JP2014125977A Active JP6137626B2 (ja) 2007-10-12 2014-06-19 Ｒｐｅ細胞を生成する改良された方法およびｒｐｅ細胞の組成物
JP2017083243A Active JP6692768B2 (ja) 2007-10-12 2017-04-19 Ｒｐｅ細胞を生成する改良された方法およびｒｐｅ細胞の組成物
JP2020072683A Pending JP2020115882A (ja) 2007-10-12 2020-04-15 Ｒｐｅ細胞を生成する改良された方法およびｒｐｅ細胞の組成物
JP2022035111A Pending JP2022079484A (ja) 2007-10-12 2022-03-08 Ｒｐｅ細胞を生成する改良された方法およびｒｐｅ細胞の組成物
JP2024205622A Pending JP2025036424A (ja) 2007-10-12 2024-11-26 Ｒｐｅ細胞を生成する改良された方法およびｒｐｅ細胞の組成物

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2014125977A Active JP6137626B2 (ja) 2007-10-12 2014-06-19 Ｒｐｅ細胞を生成する改良された方法およびｒｐｅ細胞の組成物
JP2017083243A Active JP6692768B2 (ja) 2007-10-12 2017-04-19 Ｒｐｅ細胞を生成する改良された方法およびｒｐｅ細胞の組成物
JP2020072683A Pending JP2020115882A (ja) 2007-10-12 2020-04-15 Ｒｐｅ細胞を生成する改良された方法およびｒｐｅ細胞の組成物
JP2022035111A Pending JP2022079484A (ja) 2007-10-12 2022-03-08 Ｒｐｅ細胞を生成する改良された方法およびｒｐｅ細胞の組成物
JP2024205622A Pending JP2025036424A (ja) 2007-10-12 2024-11-26 Ｒｐｅ細胞を生成する改良された方法およびｒｐｅ細胞の組成物

Country Status (13)

Country Link
US (4) US20110274662A1 (enExample)
EP (2) EP2209888B1 (enExample)
JP (6) JP2011500024A (enExample)
KR (2) KR101849336B1 (enExample)
CN (2) CN104946591A (enExample)
AU (1) AU2008312007A1 (enExample)
CA (3) CA3006687C (enExample)
DK (1) DK2209888T3 (enExample)
ES (1) ES2764473T3 (enExample)
IL (4) IL292561A (enExample)
PL (1) PL2209888T3 (enExample)
PT (1) PT2209888T (enExample)
WO (1) WO2009051671A1 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013128477A (ja) * 2011-11-25 2013-07-04 Sumitomo Chemical Co Ltd 網膜層特異的神経細胞を製造する方法
JP2013128476A (ja) * 2011-11-25 2013-07-04 Sumitomo Chemical Co Ltd 眼杯様構造体の製造方法
JP2013128474A (ja) * 2011-11-25 2013-07-04 Sumitomo Chemical Co Ltd 網膜色素上皮細胞の製造方法
JP2013128475A (ja) * 2011-11-25 2013-07-04 Sumitomo Chemical Co Ltd 網膜組織の製造方法
WO2018003908A1 (ja) * 2016-06-30 2018-01-04 株式会社ヘリオス 移植用媒体
JP2018500906A (ja) * 2014-12-18 2018-01-18 ユニヴェルシテ・ピエール・エ・マリ・キュリ・（パリ・６） 網膜変性処置のためのｏｔｘ２過剰発現トランスジェニック網膜色素上皮細胞
JP2018523682A (ja) * 2015-08-18 2018-08-23 アステラス インスティテュート フォー リジェネレイティブ メディシン 臨床製剤

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG188122A1 (en) 2004-01-23 2013-03-28 Advanced Cell Tech Inc Improved modalities for the treatment of degenerative diseases of the retina
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
JP5441099B2 (ja) 2007-01-18 2014-03-12 独立行政法人理化学研究所 視細胞への分化誘導方法
ES2764473T3 (es) 2007-10-12 2020-06-03 Astellas Inst For Regenerative Medicine Métodos mejorados para producir células RPE y composiciones de células RPE
WO2009132156A1 (en) * 2008-04-22 2009-10-29 Regenerative Research Foundation Retinal pigment epithelial stem cells
WO2009148170A1 (ja) 2008-06-06 2009-12-10 独立行政法人理化学研究所 幹細胞の培養方法
ES2509567T3 (es) * 2009-08-28 2014-10-17 Cellular Dynamics International, Inc. Identificación de variación genética en tejidos afectados
WO2011055855A1 (en) * 2009-11-05 2011-05-12 Riken A method for differentiation induction in cultured stem cells
WO2011063005A2 (en) 2009-11-17 2011-05-26 Advanced Cell Technology, Inc. Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
CA2783699C (en) 2009-12-08 2019-01-15 Case Western Reserve University Primary amine compounds for treating ocular disorders
ES2874953T3 (es) * 2010-07-23 2021-11-05 Astellas Inst For Regenerative Medicine Métodos para la detección de subpoblaciones raras de células y composiciones muy purificadas de células
FI20106354A0 (fi) * 2010-12-20 2010-12-20 Suomen Punainen Risti Veripalvelu Menetelmä ihmisen retinan pigmentti-epiteelisolujen valmistamiseksi
JP6223963B2 (ja) 2011-05-18 2017-11-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 網膜疾患を処置するための組成物および方法
CA2855941A1 (en) * 2011-11-14 2013-05-23 Advanced Cell Technology, Inc. Pharmaceutical preparations of human rpe cells and uses thereof
JP6012164B2 (ja) * 2011-11-25 2016-10-25 住友化学株式会社 多能性幹細胞由来の組織の凍結保存方法
CN113817679A (zh) * 2011-11-25 2021-12-21 住友化学株式会社 制备视网膜组织和视网膜相关细胞的方法
KR102108245B1 (ko) 2011-11-30 2020-05-08 아스텔라스 인스티튜트 포 리제너러티브 메디슨 중간엽 간질 세포 및 이에 관련된 용도
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
US10519422B2 (en) * 2012-02-29 2019-12-31 Riken Method of producing human retinal pigment epithelial cells
CN104471059B (zh) 2012-07-12 2018-04-17 珠海横琴爱姆斯坦生物科技有限公司 人胚胎干细胞衍生的间充质样干细胞、方法及其应用
EP3973967A1 (en) * 2012-12-21 2022-03-30 Astellas Institute for Regenerative Medicine Methods for production of platelets from pluripotent stem cells and compositions thereof
US20150368713A1 (en) 2013-02-01 2015-12-24 THE UNITED STATES OF AMERICAN, as represented by the Secretary, Department of Health and Human Serv METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs)
AU2014246962A1 (en) * 2013-04-03 2015-11-19 Tampereen Yliopisto Methods and media for differentiating eye cells
EP3037524B8 (en) 2013-08-23 2020-03-04 Sumitomo Chemical Company, Limited Method for producing retinal tissue and retina-related cells
EP3080248A1 (en) 2013-12-11 2016-10-19 Pfizer Limited Method for producing retinal pigment epithelial cells
CN107109367B (zh) 2014-10-24 2021-08-10 大日本住友制药株式会社 神经组织的制备方法
ES2880353T3 (es) 2014-10-24 2021-11-24 Sumitomo Dainippon Pharma Co Ltd Método de producción de tejido retiniano
MX2017008737A (es) 2014-12-30 2018-01-25 Cell Cure Neurosciences Ltd Poblaciones de celulas rpe y metodos para generar las mismas.
EA201791518A1 (ru) * 2014-12-30 2017-10-31 Селл Кьюр Нейросайансес Лтд. Способы лечения заболеваний сетчатки
EP4343331A3 (en) 2015-03-23 2024-06-19 Astellas Institute for Regenerative Medicine Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors
AU2016318774B2 (en) 2015-09-08 2022-08-18 FUJIFILM Cellular Dynamics, Inc. MACS-based purification of stem cell-derived retinal pigment epithelium
ES2971677T3 (es) 2015-09-08 2024-06-06 Sumitomo Pharma Co Ltd Método para la producción de tejido retiniano
ES2970537T3 (es) 2015-09-08 2024-05-29 Us Health Método para la diferenciación reproducible de células epiteliales del pigmento retiniano de calidad clínica
US10865381B2 (en) 2015-10-20 2020-12-15 FUJIFILM Cellular Dynamics, Inc. Multi-lineage hematopoietic precursor cell production by genetic programming
JP6987769B2 (ja) 2015-10-26 2022-01-05 セル キュア ニューロサイエンシズ リミテッド 網膜色素上皮細胞の調製法
CA3021828A1 (en) 2016-04-22 2017-10-26 Sumitomo Dainippon Pharma Co., Ltd. Method for producing retinal tissue
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
MX2019011897A (es) 2017-04-18 2019-11-28 Fujifilm Cellular Dynamics Inc Celulas efectoras inmunitarias especificas de antigenos.
US12090252B2 (en) 2017-09-14 2024-09-17 Riken Method for producing retinal tissues
CN107760649B (zh) * 2017-11-02 2021-03-30 北京全式金生物技术有限公司 一种用于人神经系统细胞培养和人多能性干细胞向神经系统细胞分化的营养添加剂
KR102198942B1 (ko) * 2019-07-02 2021-01-05 의료법인 성광의료재단 Pedf를 발현하거나 모세포에 비하여 pedf를 과발현하도록 유전적으로 조작된 중간엽 줄기세포
CN114450418A (zh) * 2019-07-19 2022-05-06 东京毅力科创株式会社 细胞的分化状态的评价方法
MX2022005134A (es) 2019-10-30 2022-05-30 Astellas Inst For Regenerative Medicine Metodos para producir celulas del epitelio pigmentario retiniano.
EP4306634A4 (en) 2021-03-09 2025-03-26 Riken METHOD FOR PRODUCING HYPOIMMUNOGENIC RETINAL PIGMENT EPITHELIAL CELLS
US20250188412A1 (en) 2022-03-16 2025-06-12 Sumitomo Pharma Co., Ltd. Transplantation medium
WO2023201361A1 (en) 2022-04-15 2023-10-19 Aspen Neuroscience, Inc. Methods of classifying the differentiation state of cells and related compositions of differentiated cells
WO2024172043A1 (ja) 2023-02-14 2024-08-22 住友ファーマ株式会社 網膜色素上皮裂孔の治療薬
CN118497111B (zh) * 2024-07-17 2024-11-08 中国农业大学 一种提高卵子体外成熟质量及体外受精后胚胎妊娠率的组合物、方法及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001508302A (ja) * 1997-01-10 2001-06-26 ライフ テクノロジーズ，インコーポレイテッド 胚性幹細胞血清置換

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610753A (en) 1991-12-12 1997-03-11 Eastman Kodak Company Optical design of laser scanner to reduce thermal sensitivity
DE69329556D1 (de) 1993-04-30 2000-11-16 Photogenesis Inc Transplantation des retinalen pigmentepithels
DE19609838A1 (de) 1996-03-13 1997-09-18 Boehringer Mannheim Gmbh Verfahren und Teststreifen zur Bestimmung eines Analyten
US6878544B2 (en) 1996-04-19 2005-04-12 Neurotech Sa Retinal cell lines with extended life-span and their applications
US20040086494A1 (en) 1996-10-07 2004-05-06 John Constance Mary Immune privileged cells for delivery of proteins and peptides
US6331406B1 (en) 1997-03-31 2001-12-18 The John Hopkins University School Of Medicine Human enbryonic germ cell and methods of use
AU9040098A (en) 1997-09-10 1999-03-29 University Of Florida Compounds and method for the prevention and treatment of diabetic retinopathy
WO1999034834A1 (en) 1998-01-02 1999-07-15 Titan Pharmaceuticals, Inc. Use of pigmented retinal epithelial cells for creation of an immune privilege site
CA2321203A1 (en) 1998-03-02 1999-09-10 Compucyte Corp. Selective cell analysis
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
JP2003514516A (ja) 1999-10-28 2003-04-22 ユニバーシティ オブ マサチューセッツ 多能性細胞と細胞株の雌性発生的または雄性発生的産生および分化した細胞と組織を産生するためのその使用
WO2001050848A2 (en) 2000-01-07 2001-07-19 Oregon Health And Science University Clonal propagation of primate offspring by embryo splitting
US6602711B1 (en) 2000-02-21 2003-08-05 Wisconsin Alumni Research Foundation Method of making embryoid bodies from primate embryonic stem cells
US20030084471A1 (en) 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
US6458589B1 (en) 2000-04-27 2002-10-01 Geron Corporation Hepatocyte lineage cells derived from pluripotent stem cells
US20040053869A1 (en) 2000-08-19 2004-03-18 Peter Andrews Stem cell differentiation
US6576464B2 (en) 2000-11-27 2003-06-10 Geron Corporation Methods for providing differentiated stem cells
US6699493B2 (en) 2000-11-29 2004-03-02 Oculex Pharmaceuticals, Inc. Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
DE10108412B4 (de) 2001-02-21 2006-03-09 Cevec Pharmaceuticals Gmbh Pigmentepithelzelle des Auges, ihre Herstellung und Verwendung in der Therapie einer Augen- oder Nervenerkrankung
EP1393066A4 (en) 2001-05-15 2006-01-25 Rappaport Family Inst For Res INSULIN-PRODUCING CELLS DERIVED FROM HUMAN EMBRYONIC STEM CELLS
IL159580A0 (en) 2001-07-12 2004-06-01 Geron Corp Cells of the cardiomyocyte lineage produced from human pluripotent stem cells
WO2003046141A2 (en) 2001-11-26 2003-06-05 Advanced Cell Technology, Inc. Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
GB2399823B (en) 2001-12-07 2006-02-15 Geron Corp Islet cells from primate pluripotent stem cells
AU2002366641A1 (en) 2001-12-11 2003-06-23 Fibrogen, Inc. Methods for inhibiting ocular processes
WO2003060083A2 (en) 2002-01-15 2003-07-24 Advanced Cell Technology, Inc. Cloning b and t lymphocytes
CA2482904A1 (en) 2002-04-18 2003-10-23 Lynkeus Biotech Gmbh Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification
US20040091936A1 (en) 2002-05-24 2004-05-13 Michael West Bank of stem cells for producing cells for transplantation having HLA antigens matching those of transplant recipients, and methods for making and using such a stem cell bank
US7422736B2 (en) * 2002-07-26 2008-09-09 Food Industry Research And Development Institute Somatic pluripotent cells
US7824671B2 (en) 2002-10-04 2010-11-02 Tissuetech, Inc. Retinal pigment epithelial cell cultures on amniotic membrane and transplantation
AU2003302020B2 (en) 2002-11-14 2008-01-31 Ethicon Endo-Surgery, Inc. Methods and devices for detecting tissue cells
US20040156878A1 (en) 2003-02-11 2004-08-12 Alireza Rezania Implantable medical device seeded with mammalian cells and methods of treatment
EP1599730A2 (en) 2003-03-03 2005-11-30 Kouyama, Yoshihisa Methods and apparatus for use in detection and quantitation of various cell types and use of optical bio-disc for performing same
WO2004098285A2 (en) 2003-05-08 2004-11-18 Cellartis Ab Cryopreservation of human blastocyst-derived stem cells by use of a closed straw vitrification method
KR100569168B1 (ko) 2003-08-08 2006-04-07 (주)아비코아생명공학연구소 조류 정원줄기세포의 배양방법 및 이에 의해 수득한 조류정원줄기세포
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
SG188122A1 (en) * 2004-01-23 2013-03-28 Advanced Cell Tech Inc Improved modalities for the treatment of degenerative diseases of the retina
EP1743023A1 (en) 2004-05-07 2007-01-17 Wisconsin Alumni Research Foundation Method of forming mesenchymal stem cells from embryonic stem cells
US6945971B1 (en) 2004-07-19 2005-09-20 Gwon Arlene E Controlled ocular lens regeneration
EP1799810A2 (en) 2004-10-12 2007-06-27 Technion Research & Development Foundation Ltd. Isolated primate embryonic cells and methods of generating and using same
CA3015835A1 (en) 2004-11-04 2006-05-18 Astellas Institute For Regenerative Medicine Derivation of embryonic stem cells
US7893315B2 (en) 2004-11-04 2011-02-22 Advanced Cell Technology, Inc. Derivation of embryonic stem cells and embryo-derived cells
CN102220280A (zh) 2005-02-11 2011-10-19 新加坡科技研究局 增殖干细胞的方法
EP1893748A1 (en) 2005-05-17 2008-03-05 Reliance Life Sciences Pvt., Ltd. Establishment of a human embryonic stem cell line using mammalian cells
WO2006126972A1 (en) 2005-05-27 2006-11-30 Agency For Science, Technology And Research Method of delivering nucleic acid molecules into embryonic stem cells using baculoviral vectors
EP1909565A2 (en) 2005-08-03 2008-04-16 Interface Multigrad Technology (IMT) Ltd. Somatic cells for use in cell therapy
JP4926615B2 (ja) 2006-08-29 2012-05-09 太陽化学株式会社 ガラクトマンナン酵素分解物の製造方法
KR100832592B1 (ko) 2006-08-17 2008-05-27 박현숙 폴리머 막을 이용한 줄기세포와 피더세포의 공배양방법
ZA200901914B (en) 2006-09-22 2010-06-30 Riken Stem cell culture medium and method
ES2530370T5 (es) * 2007-04-18 2018-05-28 Hadasit Medical Research Services & Development Limited Células del epitelio pigmentario de la retina derivadas de células madre
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
ES2764473T3 (es) 2007-10-12 2020-06-03 Astellas Inst For Regenerative Medicine Métodos mejorados para producir células RPE y composiciones de células RPE
HU0700675D0 (en) 2007-10-15 2007-12-28 Mta Tamogatott Kutatohelyek Ir Method for monitoring stem cell differentiation
US20090226955A1 (en) 2007-12-21 2009-09-10 University Of Miami Immortalized retinal pigmented epithelial cells
US20090233324A1 (en) 2008-03-11 2009-09-17 Kopf-Sill Anne R Methods for Diagnosing Cancer Using Samples Collected From A Central Vein Location or an Arterial Location
WO2009132156A1 (en) * 2008-04-22 2009-10-29 Regenerative Research Foundation Retinal pigment epithelial stem cells
US8652123B2 (en) 2008-09-02 2014-02-18 Geoffrey C. GURTNER Methods and devices for improving the appearance of tissue
WO2011063005A2 (en) 2009-11-17 2011-05-26 Advanced Cell Technology, Inc. Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
ES2874953T3 (es) 2010-07-23 2021-11-05 Astellas Inst For Regenerative Medicine Métodos para la detección de subpoblaciones raras de células y composiciones muy purificadas de células
EP2702135B1 (en) 2011-04-29 2019-04-17 University of Southern California Method of cryopreservation of stem cell-derived retinal pigment epithelial cells on polymeric substrate
CA2855941A1 (en) 2011-11-14 2013-05-23 Advanced Cell Technology, Inc. Pharmaceutical preparations of human rpe cells and uses thereof
US9850463B2 (en) 2012-02-01 2017-12-26 The Regents Of The University Of California Methods of culturing retinal pigmented epithelium cells, including xeno-free production, RPE enrichment, and cryopreservation
ES2688019T3 (es) 2012-06-05 2018-10-30 The Regents Of The University Of California Métodos y composiciones para la producción acelerada de células epiteliales pigmentadas retinianas a partir de células pluripotentes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001508302A (ja) * 1997-01-10 2001-06-26 ライフ テクノロジーズ，インコーポレイテッド 胚性幹細胞血清置換

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6013032930; Ｍｅｔｈｏｄｓ　Ｅｎｚｙｍｏｌ．，Ｖｏｌ．４１８（２００６）ｐ．１６９-１９４ *
JPN6013032931; Ｃｌｏｎｉｎｇ　ａｎｄ　Ｓｔｅｍ　Ｃｅｌｌｓ，Ｖｏｌ．８，Ｎｏ．３（２００６）ｐ．１８９-１９９ *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013128476A (ja) * 2011-11-25 2013-07-04 Sumitomo Chemical Co Ltd 眼杯様構造体の製造方法
JP2013128474A (ja) * 2011-11-25 2013-07-04 Sumitomo Chemical Co Ltd 網膜色素上皮細胞の製造方法
JP2013128475A (ja) * 2011-11-25 2013-07-04 Sumitomo Chemical Co Ltd 網膜組織の製造方法
JP2013128477A (ja) * 2011-11-25 2013-07-04 Sumitomo Chemical Co Ltd 網膜層特異的神経細胞を製造する方法
US11865189B2 (en) 2014-12-18 2024-01-09 Sorbonne Universite Transgenic RPE cells overexpressing OTX2 for the treatment of retinal degeneration
JP2018500906A (ja) * 2014-12-18 2018-01-18 ユニヴェルシテ・ピエール・エ・マリ・キュリ・（パリ・６） 網膜変性処置のためのｏｔｘ２過剰発現トランスジェニック網膜色素上皮細胞
JP2018523682A (ja) * 2015-08-18 2018-08-23 アステラス インスティテュート フォー リジェネレイティブ メディシン 臨床製剤
US12419958B2 (en) 2015-08-18 2025-09-23 Astellas Institute For Regenerative Medicine Clinical formulations
US11013808B2 (en) 2015-08-18 2021-05-25 Astellas Institute For Regenerative Medicine Clinical formulations
JP2022040140A (ja) * 2015-08-18 2022-03-10 アステラス インスティテュート フォー リジェネレイティブ メディシン 臨床製剤
JP7043392B2 (ja) 2015-08-18 2022-03-29 アステラス インスティテュート フォー リジェネレイティブ メディシン 臨床製剤
US11957754B2 (en) 2015-08-18 2024-04-16 Astellas Institute For Regenerative Medicine Clinical formulations
JP7449915B2 (ja) 2015-08-18 2024-03-14 アステラス インスティテュート フォー リジェネレイティブ メディシン 臨床製剤
WO2018003908A1 (ja) * 2016-06-30 2018-01-04 株式会社ヘリオス 移植用媒体
US11524035B2 (en) 2016-06-30 2022-12-13 Healios K.K. Transplantation medium
JP7067744B2 (ja) 2016-06-30 2022-05-16 株式会社ヘリオス 移植用媒体
JPWO2018003908A1 (ja) * 2016-06-30 2019-07-11 株式会社ヘリオス 移植用媒体

Also Published As

Publication number Publication date
EP2209888A1 (en) 2010-07-28
WO2009051671A1 (en) 2009-04-23
CA3006687C (en) 2024-01-09
CA3177952A1 (en) 2009-04-23
US20220049217A1 (en) 2022-02-17
IL324350A (en) 2025-12-01
KR101849329B1 (ko) 2018-04-16
ES2764473T3 (es) 2020-06-03
IL246181A0 (en) 2016-07-31
AU2008312007A1 (en) 2009-04-23
EP2209888B1 (en) 2019-12-04
CA2702386A1 (en) 2009-04-23
PL2209888T3 (pl) 2020-05-18
US20150086512A1 (en) 2015-03-26
JP2025036424A (ja) 2025-03-14
KR20160045933A (ko) 2016-04-27
EP2209888A4 (en) 2011-02-09
JP6137626B2 (ja) 2017-05-31
PT2209888T (pt) 2020-01-17
CN104946591A (zh) 2015-09-30
IL204956A0 (en) 2010-11-30
IL204956A (en) 2016-06-30
JP2014168482A (ja) 2014-09-18
JP2022079484A (ja) 2022-05-26
US20190062703A1 (en) 2019-02-28
JP2017136088A (ja) 2017-08-10
US20110274662A1 (en) 2011-11-10
US10077424B2 (en) 2018-09-18
CN101878295A (zh) 2010-11-03
KR20100065373A (ko) 2010-06-16
EP3636748A1 (en) 2020-04-15
IL292561A (en) 2022-06-01
KR101849336B1 (ko) 2018-04-16
JP6692768B2 (ja) 2020-05-13
JP2020115882A (ja) 2020-08-06
CA2702386C (en) 2018-07-24
CA3006687A1 (en) 2009-04-23
DK2209888T3 (da) 2020-01-20

Similar Documents

Publication Publication Date Title
JP6137626B2 (ja) Ｒｐｅ細胞を生成する改良された方法およびｒｐｅ細胞の組成物
US20240148784A1 (en) Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
AU2025205051A1 (en) Improved methods of producing RPE cells and compositions of RPE cells
HK40026818A (en) Improved methods of producing rpe cells and compositions of rpe cells
HK1149945A (en) Improved methods of producing rpe cells and compositions of rpe cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111003

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130703

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131002

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140725

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140818

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20141024

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20150311